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Abstract
Lung cancer is the leading cause of cancer mortality in the United States with non-small cell lung cancer adenocarcinoma 
being the most common histological type. Early perturbations in cellular metabolism are a hallmark of cancer, but the 
extent of these changes in early stage lung adenocarcinoma remains largely unknown. In the current study, an integrated 
metabolomics and proteomics approach was utilized to characterize the biochemical and molecular alterations between 
malignant and matched control tissue from 27 subjects diagnosed with early stage lung adenocarcinoma. Differential 
analysis identified 71 metabolites and 1102 proteins that delineated tumor from control tissue. Integrated results indicated 
four major metabolic changes in early stage adenocarcinoma (1): increased glycosylation and glutaminolysis (2); elevated 
Nrf2 activation (3); increase in nicotinic and nicotinamide salvaging pathways and (4) elevated polyamine biosynthesis 
linked to differential regulation of the s-adenosylmethionine/nicotinamide methyl-donor pathway. Genomic data from 
publicly available databases were included to strengthen proteomic findings. Our findings provide insight into the 
biochemical and molecular biological reprogramming that may accompany early stage lung tumorigenesis and highlight 
potential therapeutic targets.
Introduction
Lung cancer continues to be the leading cause of cancer-
related deaths for men and women in the United States and 
worldwide (1). While clinical studies show that low dose spiral 
computerized tomography can reduce lung cancer mortality 
by 20%, its use has been hindered by high false positive rates 
(1) largely because of difficulty distinguishing between benign 
and malignant solid pulmonary nodules (2), which leads 
to over-treatment, anxiety, and use of invasive procedures. 
Although false positive rates can be reduced with Positron 
Emission Tomography - Computed Tomography (PET-CT), a 
more comprehensive understanding of the underlying bio-
chemical and molecular perturbations that accompany tumo-
rigenesis is needed. Such knowledge would be instrumental in 
elucidating ‘lung cancer’ signatures in addition to identifying 
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molecular drivers of tumorigenesis, candidate targets of inter-
vention and to aid with diagnosis by identifying candidate bio-
markers for clinical use.
Early perturbations in cellular metabolism are a hallmark of 
cancer (3). Recent advances in mass spectrometry have enabled 
comprehensive profiling of lipids, carbohydrates, amino acids, 
organic acids and nucleotides allowing for global evaluation of 
metabolic alterations that occur in a variety of biological matri-
ces (4,5). Metabolomics has enabled new insights into the pathol-
ogy of cancer and revealed new biomarkers potentially useful 
for diagnosis and prognosis (6). However, to-date, investigations 
of lung cancer have been limited and studies that have looked at 
blood plasma are limited by small sample sizes with mixed his-
tologies (7–10). Recently, we compared the metabolome of early 
stage (stage IA/IB) non-small cell lung cancer (NSCLC) adenocar-
cinoma and matched control tissue and identified metabolomic 
evidence of decreased glucose levels, changes in cellular redox 
status, elevations in nucleotide metabolites, reduced purine 
salvage, increased de novo purine synthesis and increased pro-
tein glycosylation (5). While such knowledge is instrumental 
for understanding the underlying biochemical alterations that 
accompany tumorigenesis, it may still be insufficient to com-
pletely resolve complex biological systems or pathologies. 
Therefore, the combination of multiple ‘omic’ platforms is of 
considerable value and presents a more accurate representation 
of the organismal phenotype under a pathological state. In this 
context, given the direct relationship between metabolites as 
substrate and products of their related enzymes, the integration 
of proteomics and metabolomics serves as a particularly power-
ful approach to study lung tumorigenesis.
In the current investigation, we combined metabolomics and 
proteomics data utilizing a ‘systems biology’ approach to charac-
terize alterations at the biochemical and molecular level of lung 
adenocarcinoma tissue compared to matched non-malignant 
tissue (control) in a subset of subjects (n = 27) from our initial 
metabolomics (5) using described previously strategies (11). We 
further coupled these findings with gene expression data from 
the Gene Expression Omnibus (GEO) database. We hypothesize 
that identification of cancer-induced cellular and tissue-level 
biochemical and molecular changes offers a more robust method 
for identification of candidate diagnostic markers and targets of 
therapeutic intervention and will improve our understanding of 
the changes that accompany adenocarcinoma tumorigenesis.
Materials and methods
Sample acquisition
De-identified malignant and adjacent non-malignant (control) lung tis-
sues were harvested in the operating room from patients having resection 
for NSCLC, none of whom received preoperative treatment. The matching 
control lung tissue was always taken from areas 8–10 cm removed from 
the cancer bed. Two to three tissue pieces were aliquoted into 1.5 ml Nunc 
vials in the operating room after resection of the cancer, and frozen in 
liquid nitrogen within 30 s. Each vial was barcoded, and stored at −80°C. 
Specimens were annotated for diagnosis (including stage), age, gender, 
race, histology and smoking status (pack-years). For this study, the follow-
ing criteria was used: (a) current or former smokers, (b) adenocarcinoma 
histology, (c) pathological stage IA or IB and (d) signed the IRB consent 
form.
Metabolomics analysis
The MiniX database (5) was used as a Laboratory Information Management 
System and for sample randomization prior to all analytical procedures. 
Sample identifications were kept blinded during the entire metabolomics 
analysis to minimize bias. Sample preparation and metabolomics anal-
yses were described previously (5). Mass spectrometry metabolomics 
data have been deposited to the Metabolomics Workbench (http://www. 
metabolomicsworkbench.org) with dataset identifier ST000619.
Proteomic analysis of tissues
Paired tissue samples from 27 current or former smokers with early 
stage (IA/IB) NSCLC adenocarcinoma were assessed for alterations in the 
metabolome and proteome (Table 1). The mean age and smoking packs 
per year for subjects were 71 and 35, respectively, with more females than 
males (Table 1). Tissue samples were minced into two to three pieces and 
rinsed with cold PBS. One hundred microliters of HB buffer [0.25 M sucrose, 
20 mM Hepes-KOH, containing protease inhibitors (Roche)] was added to 
each sample, followed by homogenization for 3 min (Bullet Blender Storm, 
Wisbiomed) as described previously (12). N-glycans were released, also 
described previously (12), and ethanol precipitated tissue samples were 
used for proteomic analysis. Protein pellets were solubilized in 100  µL 
of 6 M urea in 50  mM ammonium bicarbonate. Dithiothreitol (200  mM) 
was added (final concentration of 5 mM), and samples were incubated for 
30 min at 37°C, followed by addition of 20 mM iodoacetamide (IAA) (final 
concentration of 15mM), with incubation for 30 min (RT), and then 20 µl 
200 mM DTT added to quench the iodoacetamide reaction. Lys-C/trypsin 
(Promega, Madison, WI, USA) was next added (1:25 enzyme:protein ratio), 
incubated (4 h at 37°C), then diluted to <1 M urea with 50 mM ammonium 
bicarbonate, and digested overnight at 37°C. Samples were desalted (C18 
Macro Spin columns, Nest Group) and lyophilized. Samples were dissolved 
in 2% ACN/0.1% TFA for LC MS/MS analysis
LC-MS/MS analysis
Samples were randomized into eight blocks of four normal and four 
tumor samples to keep identification of samples unknown during LC-MS/
MS analysis. Three technical replicates were acquired for each sample 
resulting in 162 total LC-MS/MS analyses. LC separation was done on a 
Waters Nano Acquity UHPLC (Waters Corporation, Milford, MA, USA) with 
a Proxeon nanospray source. Mass spectra was collected on an Orbitrap 
Q Exactive Plus mass spectrometer (Thermo Fisher Scientific, Waltham, 
MA, USA) in a data-dependent mode with one MS precursor scan followed 
by 15 MS/MS scans as described previously (13). Detailed information on 
instrument parameters and mass spectra collection is provided in the 
Supplemental Materials and Methods. The mass spectrometry proteomics 
data have been deposited to the ProteomeXchange Consortium (14) via 
the PRIDE partner repository with the dataset identifier PXD002612.
Abbreviations 
DPYD  dihydropyrimidine dehydrogenase
FDR  false discovery rate
LDCT  low dose spiral computerized tomography
NAD  nicotinamide dinucleotide adenine
NAMPT  nicotinamide phosphoribosyltransferase
NAPRT  nicotinate phosphoribosyltransferase
NSCLC  non-small cell lung cancer
PARPs  poly(ADP)ribose polymerases
PPP  pentose phosphate pathway
SAM  s-adenosylmethionine




By stage (NSCLC adenocarcinoma)
 IA, N (%) 15 (55.6%)
 IB, N (%) 12 (44.4%)
Gender (M/F) (10/17)
Age (mean ± SD) 71 ± 9
Smoking packs per year (mean ± SD) 35 ± 27
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Protein identification
Protein identification was performed similarly to Zhang et  al. (15). 
Additional details are provided in Supplemental Materials and Methods.
Statistical analysis
Detailed information regarding statistical analysis is provided in 
Supplemental Materials and Methods.
Proteomic (n = 3026) and metabolomic (n = 462) variables were merged 
for matched control and adenocarcinoma tissue for 27 patients. Mixed 
effects models were calculated to identify differentially regulated proteins 
and metabolites between adenocarcinoma and control tissues. Models 
were fit to measure variables given patient age, gender, pack-years of 
smoking history and cancer status with patient identifiers included as a 
random factor to account for the correlation of measurements from the 
same patient. A chi-squared test was used to assess the significance of 
metabolic differences through comparison of the full model to a reduced 
model not including a cancer term. The significance levels (i.e. P-values) 
were adjusted for multiple hypothesis testing according to Benjamini and 
Hochberg at a false discovery rate (FDR) of 5% (abbreviated pFDR < 0.05).
Gene expression analysis
Transcriptomic profiling data of 59 NSCLC adenocarcinomas (78% stage I) 
and 59 adjacent non-malignant tissue from Selamat et al. (16) was down-
loaded from the GEO database (GEO accession number GSE32863). The 
experiment was conducted using Illumina HumanWG-6 v3.0 expression 
BeadChip platform (16). Detailed information of the patient characteristics 
is provided elsewhere (16). Differential gene expression analysis between 
lung adenocarcinoma and control tissues was performed with an online 
tool GEO2R (http://www.ncbi.nlm.nih.gov/geo/geo2r/) that wraps around 
two R packages: GEOquery and Linear Models for Microarray Analysis. The 
GEOquery parsed the GEO data into R and differentially expressed genes 
were identified by Linear Models for Microarray Analysis. The raw P-values 
were adjusted with Benjamini and Hochberg at a FDR of 0.05.
Pathway over-representation analysis
Pathway over-representation analysis was performed using Integrated 
Molecular Pathway Level Analysis (17). Only protein IDs and metabolites 
with a raw P-value < 0.05 were considered. Detailed information regard-
ing filtering of redundant over-represented pathways is provided in the 
Supplemental Materials and Methods.
Network analysis
Thirty-eight significantly different metabolites (pFDR < 0.05) and 1102 
significantly different proteins (raw P-value < 0.05) comparing adeno-
carcinoma with non-malignant tissues were used separately to query 
the integrated networks of metabolites, proteins and genes with Grinn, 
an R-based software tool for omic data integration (11). Grinn collects 
biochemical relationships from publicly available databases (e.g. KEGG, 
Reactome and HMDB), which include information such as associations 
between enzymatic proteins and metabolites, and gene–protein encoding 
pairs. Networks were generated in Cytoscape. The networks were mapped 
with the relative changes of metabolites, proteins and genes levels 
between lung malignant and non-malignant tissues. The purpose of sys-
tems biology software is to help synthesize data and improve presentation 
of results in order to identify concurrent and related alterations leading to 
important clues about the biological connection between specific changes 
in metabolites, which will lead to further studies demonstrating a causal 
link.
Results
Comparison of physical and biochemical 
characteristics
Metabolomics analysis identified a total of 462 compounds, 83 
with known annotations. Mixed effects models were used to 
identify 71 significantly different metabolites between control 
and adenocarcinoma tissues after adjusting for the FDR (pFDR 
< 0.05) (Supplementary Table S1, available at Carcinogenesis 
Online). Proteomics analysis yielded 3026 protein groups. Mixed 
effects models were also used to identify 1102 significantly dif-
ferent proteins (raw P-value < 0.05) between control and adeno-
carcinoma tissues; however, no protein remained significantly 
following FDR adjustment (Supplementary Table S1, available 
at Carcinogenesis Online). Gene expression data was obtained 
as described in the materials and methods section and data is 
provided in Supplementary Table S1, available at Carcinogenesis 
Online.
Pathway over-representation analysis of metabolic 
and proteomic alterations
Integrated pathway over-representation analysis of metabo-
lomic and proteomic data was used to identify significantly 
perturbed pathways in adenocarcinoma relative to control. Of 
the top 10 over-represented pathways, 5 were related to altered 
metabolism highlighted by glucose metabolism, Warburg Effect 
and gluconeogenesis (Table  2 and Supplementary Table S2, 
available at Carcinogenesis Online).
Adenocarcinoma exhibit increased glycosylation 
and glutamine utilization
Analysis of the metabolome revealed significant reductions in 
glucose and the glycolytic intermediate 3-phosphoglycerate 
whereas virtually all enzymes related to the glycolytic cascade 
were elevated (Figure 1). Downstream metabolites in the glyco-
lytic cascade serve as important precursors for other proximal 
metabolic pathways. Specifically, glucose-6-phosphate serves 
Table 2. Top 10 pathways determined from metabolomic and proteomic data results
Rank Pathway
No. of overlapping 
genes
No. of genes in 
pathway p-Value Q-Value
No. of overlapping 
metabolites
1 Metabolism 216 1427 (1485) 8.51E-23 1.66E-19 39
2 Cytoplasmic ribosomal proteins 44 88 (88) 1.62E-25 6.32E-22 0
3 Glucose metabolism 32 67 (70) 3.95E-18 2.21E-15 5
4 Superpathway of conversion of glucose to acetyl CoA 
and entry into the TCA cycle
28 48 (52) 4.42E-19 5.33E-16 3
5 Warburg effect 27 45 (45) 6.82E-19 5.33E-16 4
6 Ribosome––Homo sapiens (human) 46 134 (135) 2.31E-18 1.50E-15 0
7 Translation 59 205 (217) 6.21E-19 5.33E-16 0
8 SRP-dependent cotranslational protein targeting to 
membrane
47 154 (164) 2.01E-16 5.24E-14 0
9 Eukaryotic translation elongation 46 138 (148) 8.77E-18 4.28E-15 0
10 Gluconeogenesis 19 32 (33) 1.50E-13 2.34E-11 5
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as a branching point between the glycolytic pathway, pentose 
phosphate pathway (PPP) and pentose and glucuronate inter-
conversion pathways whereas fructose-6-phosphate serves as 
a precursor for the generation of glucosamine-6-phosphate, an 
important metabolite involved in glycosylation (Figure  1). Our 
analysis indicated adenocarcinoma-associated elevations in 
enzymes involved in both the PPP and pentose and glucuronate 
interconversion pathways (Figure 1). PPP-related enzymes were 
glucose-6-phosphate dehydrogenase and 6-phosphoglucono-
lactose whereas pentose and glucuronate interconversions-
related enzymes were phosphoglucomutase, UDP-glucose 
pyrophosphorylase 2, UDP-glucose-6 dehydrogenase and 
Figure 1. Integrated networks of lung adenocarcinoma outlining biochemical relationships between metabolites, proteins and genes related to glycolysis and proxi-
mal biosynthetic pathways. Metabolites, proteins and genes are represented by circle, square and hexagonal, respectively. Node size indicates absolute magnitude 
of change. Node color shows the direction of changes comparing lung tumor and control tissues (red: increased in adenocarcinoma; green: decreased). Gray nodes 
represent features that were not detected. Significance is determined by yellow borders (pFDR < 0.05) or black borders (raw P < 0.05). Blue edges connect metabolites 
and proteins based on their enzymatic association. Purple edges link a protein and its encoding gene. Shaded areas represent the different biosynthetic pathways.
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UDP-glucuronosyltransferase (Figure  1). Transcriptomic data 
corroborated adenocarcinoma-associated elevations in glu-
cose-6-phosphate dehydrogenase, UDP-glucose pyrophos-
phorylase 2 and UDP-glucose-6 dehydrogenase; however, 
phosphoglucomutase 1 was decreased. UDP-glucuronic acid, 
an intermediate in the pentose and glucuronate interconver-
sion pathways, was also significantly elevated in adenocarci-
noma compared to control (Figure  1). Additionally, numerous 
enzymes related to glycosylation including glutamine-fruc-
tose-6-phosphate transaminase 1, phosphoglucomutase 3 and 
UDP-N-acetylglucosamine pyrophosphorylase were increased 
in adenocarcinoma compared to control; however, only glu-
tamine-fructose-6-phosphate transaminase 1 was statistically 
significant (Figure  1 and Supplementary Table S1, available at 
Carcinogenesis Online). The adenocarcinoma-dependent eleva-
tions in these enzymes were corroborated by the elevations 
in the encoding genes, GFPT1, PGM3 and UAP1 in addition 
to glucosamine-phosphate N-acetyltransferase 1 (GNPNAT1) 
and O-linked N-acetylglucosamine (GlcNAc) transferase (OGT) 
(Figure  1). UDP-N-acetylglucosamine, the end-product of the 
hexosamine pathway and principal substrate for O-linked OGTs, 
was also significantly elevated in adenocarcinoma compared to 
control tissue (Figure 1). Also detected were increases in fucosyl-
transferases FUT6 (alpha 1–3) and FUT8 (alpha 1–6) protein lev-
els in adenocarcinomas, which support increased fucosylation 
in tumorigenesis. FUT8 is responsible for core fucosylation in 
N-linked glycans and FUT6 is involved in the biosynthesis of the 
E-selectin ligand, sialyl-Lewis X, through catalyzing transfer of 
fucose from GDP-beta-fucose to alpha-2,3 sialylated substrates. 
FUT6 was not detected in control tissues (Supplementary Table 
S1, available at Carcinogenesis Online). Also detected was FUCA1 
(fucosidase, alpha-L- 1, tissue), which selectively removes fucose 
from N-linked glycoproteins, showing a potential balancing of 
fucosylation in adenocarcinoma.
All tricarboxylic acid cycle (TCA)-related enzymes were 
elevated in adenocarcinoma relative to control (Figure  1). No 
measured TCA-related metabolites were found to differ between 
control and adenocarcinoma except for citrate, which was sig-
nificantly reduced (pFDR < 0.05) in adenocarcinoma (Figure 1). 
Glutamine, like glucose, serves as a primary carbon donor for 
the TCA cycle via entry through glutamate-to- α-ketoglutarate. 
SLC1A5, the amino-acid transporter that mediates uptake of glu-
tamine, was significantly elevated in adenocarcinoma relative 
to control in the independent dataset (Supplementary Table S1, 
available at Carcinogenesis Online). Whereas glutamine was not 
significantly different between adenocarcinoma and control, 
glutamate was significantly elevated (Figure 1). Glutaminase, the 
enzyme that mediates deamination of glutamine to glutamate, 
and SLC25A22, the mitochondrial transporter that mediates the 
transfer of glutamate across the inner mitochondrial membrane, 
were elevated 6-fold, and 125-fold in adenocarcinoma compared 
to control, respectively (Figure  1 and Supplementary Table S1, 
available at Carcinogenesis Online). SLC25A22 was also found to 
be significantly elevated in adenocarcinoma relative to con-
trol tissue (Supplementary Table S1, available at Carcinogenesis 
Online).
Adenocarcinoma display heightened antioxidant 
defense mechanisms and xenobiotic metabolizing 
pathways
Cysteine and glutamate, important components in glu-
tathione synthesis, and alpha-tocopherol, a lipophilic anti-
oxidant, were significantly elevated 1.6-, 1.3- and 2.2-fold in 
adenocarcinoma compared to control tissue, respectively, 
(Figure 2 and Supplementary Table S1, available at Carcinogenesis 
Online). Cystine, the oxidized dimer of cysteine, tended to be 
reduced in adenocarcinoma compared to control, albeit not sta-
tistically significant (raw P-value: 0.057) (Figure 2). SLC7A11, the 
sodium-dependent cystine-glutamate antiporter that facilitates 
cystine uptake, was significantly elevated in adenocarcinoma 
relative to control tissue (Supplementary Table S1, available at 
Carcinogenesis Online). While we did not detect cystathionine 
nor the enzymes in the transsulfuration pathway, transcrip-
tomic data on adenocarcinoma tissue indicated significant 
increases in cystathionine gamma-lyase (CTH) suggesting that 
the increase in adenocarcinoma-associated cysteine may be a 
consequence of both cystine reduction and increased flux into 
the transsulfuration pathway (Figure 2).
In association with increases in cysteine and glutamate, 
numerous enzymes related to glutathione biosynthesis, glu-
tathione recycling, xenobiotic metabolism and redox balancing 
were elevated in adenocarcinomas relative to control tissue. 
These findings were highlighted by adenocarcinoma-dependent 
elevations in mitochondrial superoxide dismutase, thioredoxin, 
peroxiredoxin, glutathionine-s-transferases, glutathionine per-
oxidase and glutathionine reductase (Figure 2; data analysis in 
Supplementary Table S1, available at Carcinogenesis Online).
NAD metabolism in early stage lung 
adenocarcinoma
Nicotinamide dinucleotide adenine (NAD+) is an important oxi-
dizing agent vital to metabolizing pathways such as glycolysis 
and the TCA cycle. NAD+ can be produced de novo via tryptophan 
catabolism or through the nicotinic and nicotinamide salvaging 
pathways. Our analysis of the metabolome and proteome found 
significant increases in nicotinamide, a precursor for NAD+, and 
nicotinate phosphoribosyltransferase (NAPRT) in adenocarci-
noma relative to control (Figure  3). The encoding gene NAPRT 
was also found to be significantly elevated in adenocarcino-
mas relative to control in the independent dataset (Figure  3). 
Nicotinamide phosphoribosyltransferase (NAMPT), the rate-
limiting enzymes involved in NAD+ salvaging, and nicotinamide 
N-methyltransferase (NNMT) were elevated in adenocarcinoma 
compared to control (Figure  3). However, the encoding genes, 
NNMT and NAMPT, were significantly reduced in adenocarcino-
mas compared to control in the independent dataset (Figure 3).
Adenocarcinoma tissue exhibits altered one-carbon 
metabolism and polyamine biosynthesis
In addition to serving as a substrate for NAD+ biosynthesis 
nicotinamide also participates in one carbon metabolism, act-
ing as a precursor for 1-methylnicotinamide (not detected). 
NNMT, the enzyme that mediates the transfer of the methyl 
group from s-adenosylmethionine (SAM) to nicotinamide to 
generate 1-methylnicotinamide, was elevated in adenocarci-
noma relative to control (Figure 3). Consistently, our analysis of 
the proteome indicated significant adenocarcinoma-dependent 
elevations in methionine adenosyltransferase II beta (MAT2B) 
and adenosylhomocysteinase-like 1 (AHCYL1) (Figure  3). Only 
AHCYL1 was found to be elevated, whereas MAT2B was reduced 
in adenocarcinoma compared to control (Figure  3). SAM also 
serves as a precursor for s-adenosylmethionineamine (dSAM). 
dSAM provides the propylamine groups to putrescine and sper-
midine to generate spermidine and spermine, respectively, with 
a concomitant buildup of the byproduct 5-methylthioadeno-
sine (5-MTA) (Figure  3). Spermidine was significantly reduced 
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in adenocarcinoma; whereas spermidine synthase and sper-
mine synthase are elevated at both the protein and mRNA level 
(Figure  3). Moreover, 5-MTA was elevated in adenocarcinoma 
relative to control (Figure 3). Putrescine is generated through the 
decarboxylation of ornithine by ornithine decarboxylase (ODC). 
Although ornithine decarboxylase and OTC were not detected in 
this study, ornithine and citrulline were significantly reduced in 
adenocarcinomas compared to control (Figure 3).
Alterations in nucleotide metabolism 
characterized by elevations in 5,6-dihydrouracil in 
adenocarcinoma tissue
Many proteins involved in de novo pyrimidine synthesis were up-
regulated in adenocarcinoma compared to control (Figure 4). Of 
interest is the 2.7-fold increase in adenocarcinoma-associated 
5,6-dihydrouracil, a catabolic product of uracil that was also ele-
vated in tumor relative to control (Figure 4 and Supplementary 
Table S1, available at Carcinogenesis Online). The catabolism of 
uracil to 5,6-dihydrouracil is mediated by dihydropyrimidine 
dehydrogenase (DPYD), which was increased 23-fold in adeno-
carcinoma (Figure  4 and Supplementary Table S1, available at 
Carcinogenesis Online). Additionally, uridine phosphorylase, the 
enzyme mediating the catabolism of uridine to uracil, and its 
encoding gene, UPP1, were also significantly elevated in adeno-
carcinoma compared to control (Figure 4).
Noteworthy, many nicotinamide-dependent poly(ADP)ribose 
polymerases (PARPs), important components in DNA repair, 
were elevated in adenocarcinoma for which PARP10 and PARP14 
also indicated significant elevations at the mRNA level (Figure 4).
Discussion
The present study integrates proteomic and metabolomic 
data with gene expression information in order to character-
ize biochemical and molecular changes potentially associated 
with lung tumorigenesis. Specific focus was placed on NSCLC 
adenocarcinoma, since adenocarcinoma is the most com-
mon histological type of lung cancer (18), thereby minimiz-
ing bias from mixed histologies or tumor stage. Evaluation of 
early stage (Stage IA/IB) adenocarcinomas allows us to capture 
early events of tumorigenesis, important for early detection. 
Metabolites are the final output of all cellular activity and is the 
most sensitive gauge of physiological activity, especially what 
might be biologically occurring during early tumorigenesis. 
Because of the dynamic nature of connected metabolomic and 
proteomic changes and to better understand these changes in 
early stage lung adenocarcinoma, which are difficult to study 
in human tissues and we can only surmise from this inves-
tigation, more examination into this topic is needed. Future 
studies investigating flux information is warranted to better 
understand directionality of fluxes, e.g. to understand the 
Figure 2. Integrated networks of lung adenocarcinoma outlining biochemical pathways related to cysteine synthesis, glutathione synthesis and recycling and redox 
quenching. Metabolites, proteins and genes are represented by circle, square and hexagonal, respectively. Node size indicates absolute magnitude of change. Node 
color shows the direction of changes comparing lung tumor and control tissues (red: increased in adenocarcinoma; green: decreased). Gray nodes represent features 
that were not detected. Significance is determined by yellow borders (pFDR < 0.05) or black borders (raw P < 0.05). Blue edges connect metabolites and proteins based 
on their enzymatic association. Purple edges link a protein and its encoding gene. Shaded areas represent the different biosynthetic pathways.
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Figure 3. Integrated networks of lung adenocarcinoma depicting the relationship between NAD synthesis, one carbon metabolism and polyamine biosynthesis. 
Metabolites, proteins and genes are represented by circle, square and hexagonal respectively. Node size indicates absolute magnitude of change. Node color shows 
the direction of changes comparing lung tumor and control tissues (red: increased in adenocarcinoma; green: decreased). Gray nodes represent features that were not 
detected. Significance is determined by yellow borders (pFDR < 0.05) or black borders (raw P < 0.05). Blue edges connect metabolites and proteins based on their enzy-
matic association. Purple edges link a protein and its encoding gene. Shaded areas represent the different biosynthetic pathways.
Figure 4. Integrated networks illustrating relationship between metabolites, proteins and genes related to pyrimidine metabolism, uracil catabolism and DNA repair. 
Metabolites, proteins and genes are represented by circle, square and hexagonal respectively. Node size indicates absolute magnitude of change. Node color shows 
the direction of changes comparing lung tumor and control tissues (red: increased in adenocarcinoma; green: decreased). Gray nodes represent features that were 
not detected. Significance is determined by yellow borders (pFDR < 0.05) or black borders (raw P < 0.05). Blue edges connect metabolites and proteins based on their 
enzymatic association. Purple edges link a protein and its encoding gene. Shaded areas represent the different biosynthetic pathways. Arrows indicate the direction 
of the respective enzymatic reaction.
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utilization of such compounds as glutamate or glucose (19,20) 
in lung cancer tissues, as well as the magnitude of pathway 
activities, e.g. for the TCA cycle where metabolite concentra-
tions appear to remain stable even when enzyme abundances 
were up-regulated. These studies are likely better addressed 
in animal models where the process of lung carcinogenesis is 
more controlled than in human studies.
The preferential use of glucose for aerobic glycolysis and lac-
tic acid fermentation rather than oxidative phosphorylation, also 
referred to as the Warburg effect, which is a well-documented 
phenomenon that occurs in various malignancies (21). Our analy-
sis indicated that adenocarcinoma tissue displayed reductions 
in glucose and elevations in virtually all proteins involved in the 
glycolytic cascade consistent with increased glycolysis. However, 
our analysis implicates that the adenocarcinoma-associated 
increase in glycolysis is not purely to increase pyruvate and 
lactate, but to also increase the bioavailability of down-stream 
intermediates that are used as precursors for other proximal bio-
synthetic pathways such the PPP (22) and glycosylation (23). Our 
integrative analysis clearly shows that adenocarcinomas exhibit 
increased machinery involved in both the PPP and glycosylation 
(Figure 1). We have already reported that adenocarcinoma exhibit 
differential N-glycosylation patterns relative to control (12). 
O-GlcNacylation of G6PD and PFK1 has been shown to promote 
the PPP and tumor growth (23,24), suggesting a potential inter-
play between post-translational modifications of proteins by gly-
cosylation and tumor metabolism. The functional implications of 
altered glycosylation patterns remain to be determined.
Interestingly, TCA-related proteins but not metabolites were 
elevated in cancer. TCA-associate metabolites were largely 
unchanged with the exception of citrate, which was significantly 
reduced in adenocarcinoma. Glutamine, like glucose, can serve 
as a central carbon donor for the TCA cycle via entry through its 
catabolism to glutamate and subsequently α-ketoglutarate. While 
glutamine was unchanged, glutamate was significantly elevated 
in adenocarcinoma relative to control. Malignancies have been 
shown to have a strong reliance on glutamine (25). The lack of 
change in glutamine may, therefore, be attributed increased 
uptake of glutamine from the tumor microenvironment thereby 
providing steady-state levels. This is supported by the observa-
tion that SLC1A5, the amino-acid transporter that facilitates 
glutamine uptake (26), was significantly elevated in adenocarci-
noma compared to control (Supplementary Table S1, available at 
Carcinogenesis Online). The conversion of glutamine to glutamate 
is mediated by glutaminase, which was also significantly elevated 
in adenocarcinoma relative to control. Previous studies have 
demonstrated that glutamine serves as a primary carbon donor 
for oxidative phosphorylation via glutaminolysis in NSCLC (27). 
In addition, one of the main products, malic acid, serves as sub-
strate for malic enzyme that produces additional NADPH that is 
needed for both biosynthesis and reducing oxidized glutathione 
in ROS defense (19). Therefore, the reduction in citrate and evi-
dence of increased glutamine deamination via GLS and mitochon-
drial glutamate transporters (SLC25A22 and SLC25A18) suggests 
an increased utilization of glutamine as a substrate for oxida-
tive phosphorylation and NADPH production rather than glu-
cose, especially since increased glucose utilization is needed for 
glycolysis, PPP and glycosylation rather than for oxidative phos-
phorylation. The alternative, use of glutamate via citrate lyase for 
production of acetyl-CoA, would not only likely lead to higher cit-
rate levels, but may be restricted to tumors with oxygen deficien-
cies (20) which are far less likely for early stage adenocarcinomas.
Previous studies have demonstrated the dependence of 
NSCLC cancer cells to GLS1, namely the GAC splice variant in 
cells with high rates of glutaminolysis and dependence on glu-
tamine for cell growth (28). Studies in triple-negative breast 
cancer have shown that GLS1 inhibition by CB-839, an oral non-
competitive selective inhibitor of GAC and KGA splice variants 
of GLS1, resulted in significant anti-tumor activity in both a 
patient-derived xenograft (PDX) model and in JIMT-1 implanted 
CB.17 SCID mouse model (29). Therefore, targeting GLS1 may 
serve as a viable therapeutic target in NSCLC adenocarcinoma; 
however, further studies will fully determine the benefit of GLS 
inhibition in NSCLC adenocarcinoma, an aspect that cannot be 
addressed in our current study.
Reactive oxygen species are common by-products of cel-
lular reactions and bioenergetics pathways mentioned above. 
Thus, to compensate and prevent excessive buildup of poten-
tially toxic radicals, intricate defense mechanisms must be in 
place. Nrf2 is master regulator of the antioxidant response and 
xenobiotic metabolism (30). Nrf2 is constantly ubiquitinated by 
KEAP1 resulting in its rapid degradation in the proteasome (30). 
KEAP1 is frequently mutated in NSCLC adenocarcinoma, result-
ing in the liberation and nuclear translocation of Nrf2 and acti-
vation of its target genes (31). Although mutational status was 
not assessed on these samples, many Nrf2 regulated enzymes, 
particularly those related to glutathione synthesis and recy-
cling, were up-regulated in adenocarcinoma compared to con-
trol. These changes were met with similar elevations in cysteine 
and glutamate, integral components in glutathione biosynthe-
sis. DeNicola and colleagues indicated previously that Nrf2 regu-
lates serine biosynthesis in subsets of NSCLC cancers harboring 
KEAP1 mutations by controlling expression of serine/glycine bio-
synthesis enzyme genes PHGDH, PSAT1 and SHMT2 to support 
glutathione and nucleotide production (32). In our analysis, only 
SHMT2 was found to be elevated in adenocarcinoma compared 
to control (Supplementary Table S1, available at Carcinogenesis 
Online). Interestingly, we observed adenocarcinoma-associated 
reductions in cystine, the oxidized dimer of cysteine. Uptake 
of cystine is facilitated by SLC7A11, the amino-acid antiporter 
that mediates the glutamate-cystine exchange. Cystine can be 
reduced to increase intracellular cysteine availability and, sub-
sequently, regulate glutathione pools (33). Although SLC7A11 
was not detected in our proteomic data, transcriptomic data 
indicated significant increases in SLC7A11 in adenocarcinoma 
compared to control tissue (Supplementary Table S1, available 
at Carcinogenesis Online). Thus, it is possible that the elevation 
in cysteine is derived from the reduction of cystine and/or from 
serine through the transulfuration pathway. Despite this, our 
data clearly demonstrate increased antioxidant defense mecha-
nisms and elevated Nrf2 activation.
Bioenergetic pathways, such as glycolysis and the TCA cycle, 
and glutathione recycling are dependent on the availability of 
reducing equivalents that mediate energy transfer. Furthermore, 
NAD+ serves as an important modulator of redox metabolism. 
Targeting NAD+ pools has become an attractive target for thera-
peutic intervention (34). Our analysis of the metabolome indi-
cated adenocarcinoma-associated increase in nicotinamide, a 
precursor for NAD+ synthesis. Nicotinamide serves as the sub-
strate for NAMPT, the rate-limiting enzyme in the NAD+ salvag-
ing pathway (34). Although NAMPT was not significantly altered 
(P: 0.059), it tended to be elevated in lung adenocarcinoma. 
However, NAD+ can also be generated through the alternative 
nicotinate salvaging pathway for which NAPRT is the rate-lim-
iting enzyme (35), or through de novo synthesis from tryptophan 
catabolism. De novo synthesis of NAD+ from tryptophan catabo-
lism is likely to be minimal since cancer cells tend to lack at 
least one enzyme in the kynurenine pathway (36). Our analysis 
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indicated significant adenocarcinoma-dependent elevations in 
NAPRT for which the encoding gene, NAPRT, was also elevated 
in the independent transcriptomic dataset, suggesting that 
adenocarcinoma may have preferential use of nicotinate for 
NAD+ biosynthesis rather than nicotinamide. This is an impor-
tant consideration given that much focus has been given to the 
inhibition of NAMPT but not NAPRT (37,38). Recently, O’Brien 
and colleagues demonstrated that NAMPT inhibition with the 
oral NAMPT-inhibitor GNE-617 inhibited NAD+ generation by 
greater than 98% and reduced tumor volume in NAPRT-deficient 
PC3 and HT-1080 xenograft models (39). However, co-adminis-
tration of nicotinic acid markedly abrogated the growth-inhib-
itor effects of GNE-617 (39). These findings were conserved in 
patient-derived xenograft models of SAO-737 sarcoma and STO-
399 gastric cancer (39). This would suggest a negative role of 
nicotinic acid in antagonizing the beneficial effects of NAMPT 
inhibition in cancerous cells.
The nicotinamide pathway is also intricately linked to the 
polyamine biosynthesis pathway and one-carbon metabolism 
via controlling the levels of available methyl donors through SAM 
pools (40). Polyamine biosynthesis is known to be deregulated 
in various malignancies (41). This study indicates significant 
adenocarcinoma-associated reductions in ornithine, citrulline 
and spermidine, whereas 5-MTA was significantly elevated. 
5-MTA, through the action of 5′-deoxy-5′-methylthioadenosine 
phosphorylase (MTAP), is involved in SAM salvage, purine sal-
vage and spermidine synthesis (42). MTAP activity is known to 
be reduced in a wide variety of tumor types including NSCLC 
(43). It has been shown previously that increased levels of 5-MTA 
inhibit MTAP activity leading to decreased levels of polyamines 
in NSCLC (44). Based on only metabolomic evidence (5) the 
reduction in spermidine was thought to be due to inhibition of 
the polyamine pathway via increased 5-MTA. However, addi-
tional integrated proteomic data shows that spermidine syn-
thase and spermine synthase were both significantly elevated in 
adenocarcinoma, whereas MTAP was no different. spermidine 
synthase and SMS facilitate the transfer of the propylamine 
group from dSAM, derived from SAM (42), to produce spermidine 
and spermine from putrescine and spermidine, respectively, 
resulting in 5-MTA as a by-product (42). Although methionine 
was not different between cancer and control tissue, MAT2B, 
the regulatory enzyme responsible for SAM production from 
methionine, was up-regulated in adenocarcinoma tissue. Thus, 
the adenocarcinoma-associated reduction in spermidine and 
elevation in 5-MTA are more likely a consequence of increased 
polyamine biosynthesis rather than suppression. Increased flux 
into the polyamine biosynthetic pathway would also explain 
the reductions in ornithine and citrulline. Ornithine serves 
as a precursor for both putrescine and citrulline via ornithine 
decarboxylase and ornithine transcarbamylase, respectively 
(42). The coordinated reduction in both ornithine and citrul-
line and evidence of increased polyamine biosynthesis would 
indicate that ornithine is being diverted into the polyamine 
pathway. Importantly, spermidine and spermine (not detected) 
can undergo acetylation to ultimately derive at the metabolic 
end-product N1,N12-diacetylspermine. We have identified previ-
ously N1,N12-diacetylspermine as a novel pre-diagnostic marker 
of lung cancer (45). Our results suggest an increase in polyamine 
biosynthesis and provides a direct link to our previously identi-
fied diagnostic marker, N1,N12-diacetylspermine (45).
The biological versatility of nicotinamide is also connected to 
regulation of DNA repair, principally through its importance as 
a cofactor for nicotinamide-dependent PARPs. Our analysis indi-
cated adenocarcinoma elevations in numerous PARPs for which 
mRNA expressions of PARP10 and PARP14 were also significantly 
elevated in the independent dataset. PARP10 has been shown 
to interact with PCNA, a master regulator of DNA replication 
and S-phase-coupled repair, to promote stability and to protect 
against DNA alterations (46), whereas PARP14 has been linked 
to promoting the aerobic glycolysis (47). The elevation in PARPs 
coincided with a general up-regulation of machinery involved in 
pyrimidine synthesis (Figure 4). Interestingly, adenocarcinomas 
exhibited increased uracil catabolism relative to control tissue. 
In particular, uracil and 5,6-dihydrouracil were significantly ele-
vated in adenocarcinomas compared to control. These changes 
were equally met with adenocarcinoma-dependent elevations 
in UPP1 and DPYD, the enzymes that mediate the catabolism of 
uridine to uracil and 5,6-dihydrouracil, respectively. The func-
tional relevance of 5,6-dihydrouracil remains to be determined; 
however, its elevation implies elevated DPYD activity that is 
known to be increased in lung adenocarcinoma compared to 
control tissue (48). The degree of patients’ DPYD activity has 
been related to improved efficacy of cytotoxic effects from com-
mon postoperative adjuvant therapy for NSCLC anti-cancer 
drug, 5-fluorouracil and its derivatives (48,49). DPYD expression 
has also been shown to be induced upon EMT induction and 
be necessary for cells to acquire mesenchymal characteristics 
(50), a reliance that may be mediated through 5,6-dihydrouracil. 
The functional relevance of 5,6-dihydrouracil accumulation in 
NSCLC adenocarcinoma warrants further investigation.
In conclusion, our findings provide considerable insight into 
biochemical and molecular perturbations that accompany tum-
origenesis. In particular, cancer-associated changes in NSCLC 
adenocarcinoma tissue were highlighted by four major meta-
bolic changes (1) increased glycosylation and glutaminolysis 
(2), elevated Nrf2 activation (3), increase in both nicotinic and 
nicotinamide salvaging pathways and (4) elevated polyamine 
biosynthesis linked to differential regulation of the SAM/nico-
tinamide methyl-donor pathway. These findings are consistent 
with those of other lung cancer tissue studies and may highlight 
potential candidate targets for therapeutic interventions.
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